Oramed Pharmaceuticals Inc.

321 articles about Oramed Pharmaceuticals Inc.

• Oramed Patent in Canada Allowed for Oral Delivery of Proteins

  4/7/2020

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Canadian Patent Office has indicated its intent to grant the Company a patent for its invention titled "Methods and Compositions for Oral Administration of Proteins."

• Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

  4/1/2020

  Oramed Pharmaceuticals CEO provided a letter to shareholders

• Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA

  3/19/2020

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive feedback from its initial End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss Chemistry Manufacturing a

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

  2/27/2020

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $4.00 per share.

• Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial

  2/26/2020

  NEW YORK , Feb. 26, 2020 /PRNewswire/ -- Primary endpoints successfully met Results confirm significant clinical benefits of ORMD-0801 at lower dose treatment 0.95% (0.81% placebo adjusted) A1C reduction in patients treated once daily at 8mg Excellent safety profile Paves the way for FDA discussions on Phase 3 Study Confere

• Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock - Feb. 26, 2020

  2/26/2020

  Oramed Pharmaceuticals Inc.,, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

• Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

  2/26/2020

  NEW YORK and CLEVELAND, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that João Siffert, M.D., Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 27, 2020 at 11:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website, www.abeonatherapeutics.com

• Oramed to Present at BIO CEO & Investor Conference - Feb. 4, 2020

  2/4/2020

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that CEO Nadav Kidron will present a company overview at the BIO CEO & Investor Conference in New York City.

• Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board

  1/30/2020

  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Dr. Julio Rosenstock to its Scientific Advisory Board.

• Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

  1/28/2020

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent to grant the Company a patent for its invention titled "Methods and Compositions for Oral Administration of Proteins,

• Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

  1/23/2020

  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.

• Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

  1/21/2020

  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board. 

• Oramed Pharmaceuticals Issues Letter to Shareholders

  1/9/2020

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron.

• 

  BioSpace Movers & Shakers, Dec. 6

  12/6/2019

  Pharma and biotech companies strengthen their leadership teams and boards with this week's hires.

• Oramed Appoints Dr. Arie Mayer to Board of Directors

  12/5/2019

  Dr. Mayer is the current Managing Director and Chairman of the Board of Merck Life Science Israel

• Oramed to Present a Scientific Poster at International Diabetes Federation Congress

  12/2/2019

  Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will present the poster.

• Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

  11/21/2019

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Japanese patent for the technology "Protease Inhibitor – Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same" has been granted by the Japanese Patent Office

• Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

  11/19/2019

  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2019, where a panel of investigators and Key Opinion Leaders presented detailed findings from the Company's successful Phase IIb study of ORMD-0801 in the treatment of type 2 diabetes.

• Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

  11/14/2019

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801.